• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

右美沙芬在日本人群中的药代动力学及多态性氧化

Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.

作者信息

Nagai N, Kawakubo T, Kaneko F, Ishii M, Shinohara R, Saito Y, Shimamura H, Ohnishi A, Ogata H

机构信息

Department of Biopharmaceutics, Meiji College of Pharmacy, Tokyo, Japan.

出版信息

Biopharm Drug Dispos. 1996 Jul;17(5):421-33. doi: 10.1002/(SICI)1099-081X(199607)17:5<421::AID-BDD421>3.0.CO;2-9.

DOI:10.1002/(SICI)1099-081X(199607)17:5<421::AID-BDD421>3.0.CO;2-9
PMID:8830977
Abstract

The plasma concentration and cumulative urinary excretion over 34 h of dextromethorphan, free and conjugated dextrorphan, and 3-hydroxymorphinan were determined in seven healthy Japanese subjects after oral administration of 30 mg dextromethorphan hydrobromide. Conjugated metabolites were extensively present, whereas no detectable dextromethorphan or free metabolites were observed in the plasma of any subject. On average, 72% of the dose was excreted in urine within 34 h. This was detected mainly as conjugated metabolites with only slight traces of dextromethorphan and free metabolites. From the time-courses of the metabolic ratio (the ratio of urinary output of dextromethorphan to dextrorphan), the metabolic ratios seemed to become constant 7.5 h after oral administration. Phenotyping was performed using metabolic ratios in 75 unrelated healthy Japanese subjects (43 males and 32 females). The logarithmic metabolic ratio was bimodally distributed and one subject (1.3%) was identified as a poor metabolizer.

摘要

在7名健康日本受试者口服30mg氢溴酸右美沙芬后,测定了34小时内右美沙芬、游离和结合右啡烷以及3-羟基吗啡喃的血浆浓度和累积尿排泄量。结合代谢物广泛存在,而在任何受试者的血浆中均未观察到可检测到的右美沙芬或游离代谢物。平均而言,72%的剂量在34小时内随尿液排出。这主要检测为结合代谢物,仅含有微量的右美沙芬和游离代谢物。从代谢率(右美沙芬与右啡烷的尿排出量之比)的时间进程来看,口服给药7.5小时后代谢率似乎变得恒定。在75名无亲缘关系的健康日本受试者(43名男性和32名女性)中使用代谢率进行了表型分析。对数代谢率呈双峰分布,一名受试者(1.3%)被鉴定为代谢缓慢者。

相似文献

1
Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.右美沙芬在日本人群中的药代动力学及多态性氧化
Biopharm Drug Dispos. 1996 Jul;17(5):421-33. doi: 10.1002/(SICI)1099-081X(199607)17:5<421::AID-BDD421>3.0.CO;2-9.
2
Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.用于测定CYP2D6活性的新型单点血浆或唾液右美沙芬方法。
J Pharmacol Exp Ther. 1998 Jun;285(3):955-60.
3
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.CYP2D6基因多态性和奎尼丁对右美沙芬在人体内的处置及镇咳作用的影响。
Clin Pharmacol Ther. 1996 Sep;60(3):295-307. doi: 10.1016/S0009-9236(96)90056-9.
4
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.右美沙芬与右啡烷的尿代谢比值不能反映右美沙芬的口服清除率。
Drug Metab Dispos. 2005 Jul;33(7):1052-5. doi: 10.1124/dmd.104.003459. Epub 2005 Apr 8.
5
Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.肾衰竭广泛代谢者个体CYP2D6活性的评估:司巴丁与右美沙芬的比较
Clin Pharmacol Ther. 1996 May;59(5):583-92. doi: 10.1016/S0009-9236(96)90187-3.
6
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.右美沙芬对细胞色素P450 2D6(CYP2D6)表型分析的剂量依赖性。
Clin Pharmacol Ther. 1999 Nov;66(5):535-41. doi: 10.1016/S0009-9236(99)70018-4.
7
Plasma profile and pharmacokinetics of dextromethorphan after intravenous and oral administration in healthy dogs.右美沙芬在健康犬静脉注射和口服给药后的血浆特征及药代动力学
J Vet Pharmacol Ther. 2004 Oct;27(5):337-41. doi: 10.1111/j.1365-2885.2004.00608.x.
8
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.通过右美沙芬的群体药代动力学评估 CYP2D6*1、CYP2D6*2 和 CYP2D6*41 基因的活性水平。
Clin Pharmacol Ther. 2010 Nov;88(5):643-51. doi: 10.1038/clpt.2010.137. Epub 2010 Sep 29.
9
Polymorphism of dextromethorphan oxidation in South Indian subjects.
Clin Pharmacol Ther. 1999 Aug;66(2):193-200. doi: 10.1053/cp.1999.v66.99989.
10
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.将药物代谢的体外信息纳入临床试验模拟,以评估CYP2D6基因多态性对药代动力学和药效学的影响:右美沙芬作为模型应用。
J Clin Pharmacol. 2007 Feb;47(2):175-86. doi: 10.1177/0091270006294279.

引用本文的文献

1
Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan.基于生理的药代动力学(PBPK)模型研究CYP2D6基因多态性在右美沙芬代谢表型分析中的作用
Front Pharmacol. 2022 Oct 24;13:1029073. doi: 10.3389/fphar.2022.1029073. eCollection 2022.